Caribou Biosciences (NASDAQ:CRBU – Get Free Report) and Tenaya Therapeutics (NASDAQ:TNYA – Get Free Report) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, dividends, analyst recommendations, profitability, valuation, risk and earnings.
Analyst Ratings
This is a breakdown of current ratings and target prices for Caribou Biosciences and Tenaya Therapeutics, as reported by MarketBeat.com.
Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
Caribou Biosciences | 0 | 0 | 4 | 0 | 3.00 |
Tenaya Therapeutics | 0 | 0 | 6 | 0 | 3.00 |
Caribou Biosciences currently has a consensus target price of $10.20, suggesting a potential upside of 510.78%. Tenaya Therapeutics has a consensus target price of $17.33, suggesting a potential upside of 1,055.56%. Given Tenaya Therapeutics’ higher probable upside, analysts plainly believe Tenaya Therapeutics is more favorable than Caribou Biosciences.
Valuation and Earnings
Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
Caribou Biosciences | $11.48 million | 13.18 | -$102.07 million | ($1.65) | -1.01 |
Tenaya Therapeutics | N/A | N/A | -$124.08 million | ($1.44) | -1.04 |
Caribou Biosciences has higher revenue and earnings than Tenaya Therapeutics. Tenaya Therapeutics is trading at a lower price-to-earnings ratio than Caribou Biosciences, indicating that it is currently the more affordable of the two stocks.
Insider & Institutional Ownership
77.5% of Caribou Biosciences shares are held by institutional investors. Comparatively, 90.5% of Tenaya Therapeutics shares are held by institutional investors. 9.5% of Caribou Biosciences shares are held by company insiders. Comparatively, 32.8% of Tenaya Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.
Profitability
This table compares Caribou Biosciences and Tenaya Therapeutics’ net margins, return on equity and return on assets.
Net Margins | Return on Equity | Return on Assets | |
Caribou Biosciences | -1,290.81% | -45.46% | -38.07% |
Tenaya Therapeutics | N/A | -86.17% | -71.14% |
Volatility & Risk
Caribou Biosciences has a beta of 2.27, indicating that its share price is 127% more volatile than the S&P 500. Comparatively, Tenaya Therapeutics has a beta of 2.72, indicating that its share price is 172% more volatile than the S&P 500.
Summary
Tenaya Therapeutics beats Caribou Biosciences on 7 of the 12 factors compared between the two stocks.
About Caribou Biosciences
Caribou Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies in the United States and internationally. Its lead product candidate is CB-010, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapsed or refractory B cell non-Hodgkin lymphoma. The company also develops CB-011, an allogeneic anti-BCMA CAR-T cell therapy that is in phase 1 clinical trial for the treatment of relapsed or refractory multiple myeloma; and CB-012, an allogeneic anti-CD371 CAR-T cell therapy that is in phase 1 clinical trial for the treatment of relapsed or refractory acute myeloid leukemia. Caribou Biosciences, Inc. was incorporated in 2011 and is headquartered in Berkeley, California.
About Tenaya Therapeutics
Tenaya Therapeutics, Inc., a biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States. It develops its products through gene editing, cellular regeneration, and gene addition. The company is developing TN-201, a gene therapy for myosin binding protein C3-associated hypertrophic cardiomyopathy which is in phase 1 clinical trial; TN-301, a small molecule for heart failure with preserved ejection fraction which is in phase 1 clinical trial; and TN-401, a gene therapy for plakophilin 2-associated arrhythmogenic right ventricular cardiomyopathy which is in preclinical stage. It also develops an adeno-associated virus-based gene therapy designed to deliver the dworf gene for patient with dilated cardiomyopathy; and reprogramming program for heart failure due to prior myocardial infarction. Tenaya Therapeutics, Inc. was incorporated in 2016 and is headquartered in South San Francisco, California.
Receive News & Ratings for Caribou Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Caribou Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.